Pioneer Group and Novo Nordisk team up on Golden Ticket Programme for cardiometabolic health innovations
Pioneer Group, a specialist in life science infrastructure and venture building, has
teamed up with global healthcare company Novo Nordisk to launch a Golden
Ticket designed to help accelerate innovations in cardiometabolic diseases, rare
blood and rare endocrine disorders.
The Golden Ticket programme is aimed at early-stage biotech companies focused
on novel drug targets and transformational medicines in cardiometabolic disease,
with robust research plans and potential for successful research development.